Use of the Polymerase Chain Reaction Technique to Determine c‐myc Expression in Follicular Center Cell Lymphoma

We determined, in a semiquantitative fashion, the level of expression of c-myc in 18 follicular center cell lymphomas and five non-neoplastic lymph nodes using reverse transcription and the polymerase chain reaction technique (RT-PCR). With this method, RNA is extracted from lymph node specimens and reverse-transcribed to produce cDNA, which is then amplified using primers specific for c-myc sequences that span introns, thus precluding amplification of genomic DNA. Amplified products are compared with β2-microglobulin sequences co-amplified in each case as a control for the quality of RNA extracted, RT, and PCR amplification. Using cell lines derived from Burkitt's lymphomas, the RT-PCR method yielded results equivalent to standard Northern blot analysis yet required smaller quantities of tissue. The c-myc transcripts were detected in all lymphoma cases studied (seven high, 11 low expression) and in all non-neoplastic lymph nodes. High or low c-myc expression was based on comparison with non-neoplastic lymph nodes. We conclude that the RT-PCR method is a sensitive, reliable method for measuring gene expression in lymphoma tissues and may be useful for studying the role of c-myc in follicular lymphomas.

[1]  D. Longo,et al.  MYC rearrangements in histologically progressed follicular lymphomas. , 1992, Blood.

[2]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[3]  R. Shine,et al.  Why do female adders copulate so frequently? , 1992, Nature.

[4]  D. de Jong,et al.  Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. , 1991, Oncogene.

[5]  P. Levine,et al.  Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. , 1991, Blood.

[6]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[7]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[8]  E. Jaffe,et al.  Surface light chain phenotype in indolent lymphomas: Lack of prognostic significance , 1990, American journal of hematology.

[9]  M. Raffeld,et al.  Detection of occult follicular lymphoma by specific DNA amplification. , 1988, Blood.

[10]  I. Ginjaar,et al.  The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. , 1987, Journal of immunology.

[11]  S. Korsmeyer,et al.  Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. , 1987, The Journal of clinical investigation.

[12]  S. Korsmeyer,et al.  Clonal evolution of t(14;18) follicular lymphomas demonstrated by immunoglobulin genes and the 18q21 major breakpoint region. , 1987, Cancer research.

[13]  M. Oken,et al.  Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. , 1987, The New England journal of medicine.

[14]  P. Leder,et al.  The human c-myc oncogene: Structural consequences of translocation into the igh locus in Burkitt lymphoma , 1983, Cell.

[15]  J. Rowley,et al.  Identification of the constant chromosome regions involved in human hematologic malignant disease. , 1982, Science.